The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration

JAMA Ophthalmology

Volumn 132, Issue 4, 2014, Pages 456-463

  Sloan, Frank A ^a   Hanrahan, Brian W ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PEGAPTANIB;

AGE; AGED; ARGON LASER PHOTOCOAGULATION THERAPY; ARTICLE; BLINDNESS; CATARACT; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEPRESSION; DIABETIC RETINOPATHY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; ICD-9-CM; LASER COAGULATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICARE; OPHTHALMIC ARGON LASER; PHARMACEUTICAL CARE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROPENSITY SCORE; RACE DIFFERENCE; RETINA MACULA AGE RELATED DEGENERATION; THERAPY EFFECT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BLINDNESS; DEPRESSIVE DISORDER; DIFFUSION OF INNOVATION; EXUDATES AND TRANSUDATES; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; LONG-TERM CARE; MALE; MEDICARE; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84898640257     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.7647     Document Type: Article

References (35)

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012; 379 (9827): 1728-1738.
2. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102 (11): 1640-1642.
3. StewartMW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012; 87 (1): 77-88.
4. Macular Photocoagulation Study Group. Argon laser photocoagulation for idiopathic neovascularization: results of a randomized clinical trial. Arch Ophthalmol. 1983; 101 (9): 1358-1361.
5. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. Arch Ophthalmol. 1986; 104 (5): 694-701.
6. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991; 109 (9): 1220-1231.
7. Bressler NM; Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol. 2001; 119 (2): 198-207.
8. Becerra EM, Morescalchi F, Gandolfo F, et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr Drug Targets. 2011; 12 (2): 149-172.
9. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003; 87 (4): 462-468.
10. Gillies MC, Larsson J. The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration. Am J Ophthalmol. 2007; 144 (1): 134-136.
11. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003; 121 (5): 667-673.
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351 (27): 2805-2816.
13. Heier JS, Boyer DS, Ciulla TA, et al; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study [published correction appears in Arch Ophthalmol. 2007; 125 (1): 138]. Arch Ophthalmol. 2006; 124 (11): 1532-1542.
14. Stein JD, Hanrahan BW, Comer GM, Sloan FA. Diffusion of technologies for the care of older adults with exudative age-related macular degeneration. Am J Ophthalmol. 2013; 155 (4): 688-696.e1-2. doi: 10.1016/j.ajo.2012.10.003.
15. Day S, Acquah K, Lee PP, Mruthyunjaya P, Sloan FA. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol. 2011; 152 (6): 1014-1020.
16. Skaat A, Chetrit A, Belkin M, Kinori M, Kalter-Leibovici O. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol. 2012; 153 (2): 214-221.e1. doi: 10.1016/j.ajo.2011.08.035.
17. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012; 153 (2): 209-213.e2. doi: 10.1016/j.ajo.2011.10.016.
18. Hahn J, Todd P, Van der KlaauwW. Identification and estimation of treatment effects with a regression discontinuity design. Econometrica. 2001; 69 (1): 201-209.
19. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010; 128 (10): 1273-1279.
20. Coleman HR, Chan CC, Ferris FL III, Chew EY. Age-related macular degeneration. Lancet. 2008; 372 (9652): 1835-1845.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40 (5): 373-383.
22. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med. 2007; 26 (4): 734-753.
23. D'Agostino RB Jr. Propensity scoremethods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17 (19): 2265-2281.
24. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acutemyocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001; 54 (4): 387-398.
25. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70 (1): 41-55.
26. Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011; 129 (6): 709-717.
27. Brody BL, Gamst AC, Williams RA, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001; 108 (10): 1893-1901.
28. Rovner BW, Casten RJ, TasmanWS. Effect of depression on vision function in age-related macular degeneration. Arch Ophthalmol. 2002; 120 (8): 1041-1044.
29. Wysong A, Lee PP, Sloan FA. Longitudinal incidence of adverse outcomes of age-related macular degeneration. Arch Ophthalmol. 2009; 127 (3): 320-327.
30. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006; 124 (12): 1754-1760.
31. Vu HT, Keeffe JE, McCarty CA, Taylor HR. Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol. 2005; 89 (3): 360-363.
32. Coleman AL, Morgenstern H. Use of insurance claims databases to evaluate the outcomes of ophthalmic surgery. Surv Ophthalmol. 1997; 42 (3): 271-278.
33. Mitchell JB, Bubolz T, Paul JE, et al. Using Medicare claims for outcomes research. Med Care. 1994; 32 (7) (suppl): JS38-JS51.
34. Javitt JC, Zhou Z, Willke RJ. Association between vision loss and higher medical care costs in Medicare beneficiaries are greater for those with progressive vision loss. Ophthalmology. 2007; 114 (2): 238-245.
35. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997; 115 (6): 741-747.